皮肤性病

订阅

MedSci主页 / 所有栏目 / 皮肤性病

糖皮质激素在特异性皮炎中的使用原则

2022-08-03 李邻峰 MedSci原创

糖皮质激素特应性皮炎皮肤科
关注

首都医科大学附属北京友谊医院

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1701335, encodeId=26d81e01335b9, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sat Dec 31 12:47:05 CST 2022, time=2022-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899567, encodeId=6459189956ebd, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sat Oct 08 23:47:05 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600472, encodeId=73cc16004e236, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Thu Aug 04 09:47:05 CST 2022, time=2022-08-04, status=1, ipAttribution=)]
    2022-12-31 Tommy1959

    #糖皮质#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1701335, encodeId=26d81e01335b9, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sat Dec 31 12:47:05 CST 2022, time=2022-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899567, encodeId=6459189956ebd, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sat Oct 08 23:47:05 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600472, encodeId=73cc16004e236, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Thu Aug 04 09:47:05 CST 2022, time=2022-08-04, status=1, ipAttribution=)]
    2022-10-08 jinweidong

    #特异性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1701335, encodeId=26d81e01335b9, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sat Dec 31 12:47:05 CST 2022, time=2022-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899567, encodeId=6459189956ebd, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sat Oct 08 23:47:05 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600472, encodeId=73cc16004e236, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Thu Aug 04 09:47:05 CST 2022, time=2022-08-04, status=1, ipAttribution=)]
    2022-08-04 bbwznl

    #皮质激素#

    0

相关资讯

JAIP：美泊利单抗治疗重度嗜酸性粒细胞性哮喘后的糖皮质激素反应性

研究探索了在接受美泊利单抗治疗的重度嗜酸性粒细胞性哮喘患者中口服糖皮质激素的临床和抗炎作用。

风湿病患者想要正确使用糖皮质激素，看着一篇就够了！

糖皮质激素使用短疗程者可快速减药，长疗程者需缓慢减药，需遵循“先快后慢”原则。

ARD：RA患者初始治疗使用糖皮质激素后停药成功率如何？

在类风湿性关节炎(RA)患者临床试验中，糖皮质激素(GC)停药大多是成功的，尽管 22%的开始GC桥接治疗的患者在12个月时仍然或再次使用GC，在24个月时为10%。

到底该怎么吃药？ 风湿免疫病的服药时间手册！

风湿科药物这么多，到底应该怎么服药？

ARD：是什么导致SLE临床试验结果测量的不一致？

在所有试验中，大多数患者具有一致的BICLA/SRI(4)结果，双BICLA/SRI(4)反应有利于anifrolumab。在未来的SLE试验中，仔细关注基线疾病活动和监测糖皮质激素锥度变化必不可少。

ARD：托珠单抗治疗新发风湿性多肌痛(PMR-SPARE)：一项2/3期随机对照试验

该研究发现在接受快速糖皮质激素减量的新发风湿性多肌痛患者中，托珠单抗在持续无糖皮质激素缓解、复发时间和累积糖皮质激素剂量方面优于安慰剂。